(NP (NP Abnormality/NN) (PP of/IN (NP (NP Oct-1/NN DNA/NN binding/NN) (PP in/IN (NP (NP T/NN cells/NNS) (PP from/IN (NP (NP Sjogren/NN 's/POS) syndrome/NN patients/NNS)))))) ./.)
(S (NP-SBJ Primary/JJ (NP (NP (NP Sjogren/NN 's/POS) syndrome/NN) (PRN -LRB-/-LRB- (NP SS/NN) -RRB-/-RRB-))) (VP is/VBZ (NP-PRD (NP an/DT autoimmune/JJ rheumatic/JJ disease/NN) (VP characterized/VBN (NP */-NONE-) (PP by/IN (NP-LGS T/NN cell/NN hypoactivity/NN))))) ./.)
(S (S (NP-SBJ-41 *-40/-NONE-) (VP To/TO (VP understand/VB (NP (NP the/DT diminished/VBN T/NN cell/NN response/NN) (PP to/TO (NP activation/NN signals/NNS)))))) ,/, (NP-SBJ-40 we/PRP) (VP measured/VBD (NP (NP nucleoprotein/NN DNA-binding/JJ activities/NNS) (VP regulating/VBG (NP gene/NN expression/NN) (PP-TMP during/IN (NP T/NN cell/NN activation/NN)))) (S (NP-SBJ *-41/-NONE-) (VP using/VBG (NP the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN)))) ./.)
(S (NP-SBJ-42 (NP Peripheral/JJ blood/NN lymphocytes/NNS) (PP from/IN (NP 9\/19/CD SS/NN patients/NNS))) (VP were/VBD (VP found/VBN (S (NP-SBJ *-42/-NONE-) (VP to/TO (VP be/VB (ADJP-PRD defective/JJ) (PP in/IN (NP their/PRP$ ability/NN (S (NP-SBJ */-NONE-) (VP to/TO (VP bind/VB (NP (NP an/DT october/NN sequence/NN) (PRN -LRB-/-LRB- (NP Oct-1/NN) -RRB-/-RRB-)))))))))))) ./.)
(S (NP-SBJ This/DT Oct-1-binding/JJ phenotype/NN) (VP remained/VBD (ADJP-PRD stable/JJ) (PP in/IN (NP culture/NN)) (PP-TMP for/IN (NP (NP (QP up/IN to/TO 3/CD) days/NNS) (PP-TMP prior/RB to/TO (NP activation/NN))))) ./.)
(S (NP-SBJ-43 This/DT abnormality/NN) (VP was/VBD not/RB (VP seen/VBN (NP *-43/-NONE-) (PP in/IN (NP (NP-COOD (NP resting/VBG T/NN cells/NNS) nor/CC (NP T/NN cells/NNS)) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP-COOD (NP systemic/JJ lupus/NN erythematosus/NN) ,/, (NP (NP rheumatoid/JJ arthritis/NN) (PRN -LRB-/-LRB- (NP RA/NN) -RRB-/-RRB-)) ,/, or/CC (NP (NP SS/NN) (VP accompanied/VBN (NP */-NONE-) (PP by/IN (NP-LGS RA/NN)))))))))))) ./.)
(S (NP-SBJ The/DT SS/NN Oct-1/NN DNA-binding/JJ abnormality/NN) (VP correlated/VBD (ADVP significantly/RB) (PP with/IN (NP (NP an/DT inability/NN (S *ICH*-45/-NONE-)) (PP of/IN (NP cells/NNS)) (S-45 (NP-SBJ-44 */-NONE-) (VP to/TO (VP exit/VB (NP the/DT Gzero\/G1/NN cell/NN cycle/NN phase/NN) (SBAR-TMP (WHADVP-46 when/WRB) (S (NP-SBJ-47 *-44/-NONE-) (VP stimulated/VBN (NP *-47/-NONE-) (ADVP in/FW vitro/FW) (ADVP *T*-46/-NONE-)))))))))) ./.)
(S (ADVP Importantly/RB) ,/, (NP-SBJ (NP nucleoprotein/NN extracts/NNS) (VP showing/VBG (NP decreased/VBN DNA-binding/JJ activity/NN))) (VP had/VBD (NP (NP normal/JJ amounts/NNS) (PP of/IN (NP Oct-1/NN proteins/NNS)) (SBAR as/IN (S (NP-SBJ-48 */-NONE-) (VP determined/VBN (NP *-48/-NONE-) (PP by/IN (NP-LGS immunoprecipitation/NN)))))) ,/, (S (NP-SBJ */-NONE-) (VP implying/VBG (NP (NP a/DT functional/JJ defect/NN) (PP in/IN (NP the/DT Oct-1/NN protein/NN)))))) ./.)
(S (ADVP Moreover/RB) ,/, (NP-SBJ-49 defective/JJ DNA/NN binding/NN) (VP was/VBD (VP corrected/VBN (NP *-49/-NONE-) (PP by/IN (NP-LGS (NP treatment/NN) (PP with/IN (NP acid/NN phosphatase/NN)))))) ./.)
